EPISODE · Aug 10, 2020 · 35 MIN
Summer Sessions 5: Dr. Christopher Anzalone Takes RNAi Beyond The Liver
from Business Of Biotech · host Matt Pillar
We love to hear from our listeners. Send us a message. Arrowhead Pharma CEO Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Embed this episode
What this episode covers
We love to hear from our listeners. Send us a message. Arrowhead Pharma CEO Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech t...
NOW PLAYING
Summer Sessions 5: Dr. Christopher Anzalone Takes RNAi Beyond The Liver
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.